Skip to main content
TipRanks
Go Ultimate75% OFF

STELLA PHARMA CORPORATION (4888) AI Stock Analysis

0 Followers
JP:4888

STELLA PHARMA CORPORATION

(TSE/TYO:4888)

Select Model
Rating:42Neutral
Price Target:JPY 415.00â–¼(-9.78% Downside)
Action:reiterated
Date:11/18/26

The overall score is very low, driven primarily by weak financial performance. The company is unprofitable, cash flow negative, and has highly volatile revenues, which are significant risks. While the balance sheet is manageable, it does not offset the core operational challenges. Technicals show some positive price momentum, but this is a secondary factor against the poor fundamentals and unattractive valuation.

Positive Factors
High Gross MarginsConsistently high gross margins indicate that the underlying offering can retain substantial value after direct costs. If revenue stabilizes, this margin structure could provide operating leverage and support future reinvestment, although it has not yet translated into overall profitability.
Negative Factors
Severe Revenue VolatilityThe sharp reversal in revenue undermines visibility into the company’s underlying demand and commercial trajectory. Such volatility makes planning and investment harder, weakens operating leverage, and increases the risk that future revenue gains will not develop into a stable growth trend.

STELLA PHARMA CORPORATION (4888) vs. iShares MSCI Japan ETF (EWJ)

-50%0%50%100%150%200%250%300%JP:4888+90.08%EWJ+13.11%Dec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
Market Cap
JPY 17.79B
Dividend Yield
―
Average Volume (3M)
621.95K
Price to Earnings (P/E)
-17.6
Beta (1Y)
1.05
Revenue Growth
-69.92%
EPS Growth
-411.54%
Country
Japan
Employees
47
Sector
Healthcare
Sector Strength
51
Industry
Biotechnology

STELLA PHARMA CORPORATION Business Overview & Revenue Model

Company Description

Stella Pharma Corporation is a pharmaceutical company that handles the complete process of drug development, from research and manufacturing to distribution. A core area of its specialization is in therapeutic agents for boron neutron capture therapy...

STELLA PHARMA CORPORATION Financial Statement Overview

Summary

Financial performance is weak. The income statement shows persistent losses and highly volatile revenue, with a 66% drop in the latest year. Cash flow is predominantly negative, indicating a cash-burning business. The balance sheet is the only relative bright spot, with manageable debt, but overall financial health is poor.

Income Statement

22Negative

Balance Sheet

58Neutral

Cash Flow

34Negative
Financial statement breakdown
BreakdownTTMMar 2026Mar 2025Mar 2024Mar 2023Mar 2022
Income Statement
Total Revenue323.39M323.39M961.06M269.49M229.07M100.10M
Gross Profit264.07M250.56M828.72M203.69M192.36M50.73M
EBITDA-832.87M-742.15M-99.06M-723.85M-738.35M-726.86M
Net Income-853.06M-780.92M-140.81M-763.75M-778.82M-767.72M
Balance Sheet
Total Assets5.39B4.49B5.42B3.82B4.33B4.72B
Cash, Cash Equivalents and Short-Term Investments3.80B2.82B3.21B2.35B2.71B3.28B
Total Debt899.48M747.14M766.78M933.30M1.09B1.25B
Total Liabilities2.17B2.06B2.21B1.44B1.58B1.64B
Stockholders Equity3.22B2.43B3.21B2.38B2.75B3.08B
Cash Flow
Free Cash Flow0-345.32M136.50M-887.82M-853.07M-1.13B
Operating Cash Flow0-334.51M140.41M-876.84M-827.67M-1.08B
Investing Cash Flow0-15.67M287.58M-9.01M-29.93M-350.56M
Financing Cash Flow0-33.28M725.78M228.25M291.69M3.46B

STELLA PHARMA CORPORATION Technical Analysis

Technical Analysis SentimentPositive
Last Price460.00

Price Trends

50DMA403.90Positive
100DMA363.74Positive
200DMA419.95Positive

Market Momentum

MACD-1.00Negative
RSI63.96Neutral
STOCH74.79Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For JP:4888, the sentiment is Positive. The current price of 460.00 is above the 20-day moving average (MA) of 395.35, above the 50-day MA of 403.90, and above the 200-day MA of 419.95, indicating a bullish trend. The MACD of -1.00 indicates Negative momentum. The RSI at 63.96 is Neutral, neither overbought nor oversold. The STOCH value of 74.79 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for JP:4888.

STELLA PHARMA CORPORATION Peers Comparison

Overall Rating

UnderperformOutperform
Sector (51)

Financial Indicators

JP:4888 against its peers
NameOverall RatingMarket CapP/E RatioROEDividend YieldRevenue GrowthEPS Growth
Sector *51Neutral$7.86B-0.30-43.30%2.27%22.53%-2.21%
JP:4888JP:488842NeutralJPY 17.50B-17.63――-69.92%-411.54%
JP:7774JP:777442NeutralJPY 25.58B-69.38――17.05%10.47%
JP:4571JP:457141NeutralJPY 6.46B-4.26-39.57%―48.92%-46.91%
JP:4599JP:459938UnderperformJPY 7.90B-4.21―――4.85%
JP:4593JP:459337UnderperformJPY 27.92B-12.37――-51.55%52.19%

* Healthcare Sector Average

Performance Comparison

0%100%200%JP:4888JP:4571JP:4593JP:4599JP:7774Dec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
JP:4888 and its peers over the selected period
Show on chartTickerCompany NamePriceChange% Change
JP:4888STELLA PHARMA CORPORATION460.00208.0082.54%
JP:4571NanoCarrier Co., Ltd.71.00-73.00-50.69%
JP:4593Healios KK206.00-269.00-56.63%
JP:4599StemRIM Inc.126.00-152.00-54.68%
JP:7774Japan Tissue Engineering Co., Ltd.630.00145.0029.90%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.

Date of analysis: Nov 18, 2026